18:26 , Apr 5, 2019 |  BC Week In Review  |  Clinical News

Bolt's immune-stimulating antibody conjugates decrease tumor growth

Bolt said TLR agonist antibody conjugates from its Immune-Stimulating Antibody Conjugate (ISAC) platform led to immune activation and tumor clearance in preclinical cancer models. In a presentation at the American Association for Cancer Research (AACR)...
15:45 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Bolt raises $54M series B

Autoimmune company Bolt Biotherapeutics Inc. (Redwood City, Calif.) raised $54 million in a series B round led by Pivotal bioVenture Partners. Nan Fung Life Sciences along with existing investors Novo Holdings and Vivo Ventures also...